γ ′ Fibrinogen is an isoform of fi brinogen that normally constitutes about 7 % of total plasma fi brinogen, and arises from an alternative processing event in the γ chain mRNA. γ ′ Fibrinogen is a newly-emerging cardiovascular disease (CVD) risk factor that appears to have an independent association with CVD from that of total fi brinogen, which is itself a well-established CVD risk factor. γ ′ Fibrinogen shows a signifi cant association with coronary artery disease and myocardial infarction in at least four case-control studies, including the Stockholm Coronary Artery Risk Factor study and the Framingham Heart Study. γ ′ Fibrinogen is also signifi cantly associated with stroke, as shown in the Erasmus Stroke Study and others. The role of genetic polymorphisms in the association between γ ′ fi brinogen and CVD is under active investigation. γ ′ Fibrinogen increases during infl ammation, and is differentially regulated from total fi brinogen under pathologic conditions, as demonstrated in the Periodontitis and Vascular Events study. The association between γ ′ fi brinogen and venous thromboembolism remains unclear, however, with some studies showing an inverse association with γ ′ fi brinogen levels and other studies showing the opposite.
Introduction
The association between total fi brinogen levels and cardiovascular disease (CVD) is well established by many epidemiologic studies which show that fi brinogen is a signifi cant independent risk factor for CVD (1 -3) . However, possible mechanisms by which fi brin(ogen) may contribute to CVD continue to be a subject of controversy. Elevated levels of fi brinogen have been proposed to promote fi brin formation, increase platelet aggregation, increase plasma viscosity, or simply refl ect an infl ammatory state (4) , but a mechanistic role for elevated fi brinogen in CVD remains elusive. Studies have shown that a fi rst-order relationship exists between fi brinogen concentration and fi brinolysis rate (5) , suggesting that elevated fi brinogen levels may actually cause thrombosis by slowing fi brinolysis rates (6) .
γ ′ Fibrinogen
Fibrinogen is a six-chain molecule containing two copies each of the A α , B β , and γ chains, and different combinations of altered chains can be assembled, especially in fi brinogens resulting from heterozygous polymorphisms or mutations (7, 8) . The fi brinogen γ chain, in particular, has two isoforms, the γ A (also known as γ 50 or simply γ ) isoform and the γ ′ (also known as γ 57.5 or γ B) isoform that arise from alternative mRNA processing (9, 10) . The current hypothesis is that competition between spliceosome cleavage of intron 9, which removes the intron and generates the γ A mRNA, vs. polyadenylation within intron 9 at the AAUAAA site that cleaves off the 3 ′ end of the pre-mRNA to generate the γ ′ mRNA, regulates the ratio of γ A to γ ′ mRNA. The γ ′ chain is usually paired with the more abundant γ A chain. γ ′ Fibrinogen typically constitutes approximately 7 % of total fi brinogen in plasma (11 -13) , although this percentage can vary widely among individuals, particularly in pathological conditions (14 -16) .
γ ′ Fibrinogen is a newly-emerging risk marker for thrombotic disease. γ ′ Fibrinogen has several biochemical and biophysical properties that are different from the more common isoform containing only γ A chains. Some of these properties may actually contribute mechanistically to thrombosis. Clots made from γ ′ fi brinogen in the presence of coagulation factor XIII (also known as "fi brin-stabilizing factor" in earlier nomenclature) are highly resistant to fi brinolysis (6, 17, 18) , which may allow the formation of more stable thrombi. The γ ′ chain is also reported to contain a binding site for zymogen factor XIII (19, 20) . In addition, the γ ′ chain contains a binding site for thrombin (21 -24) , and clots made from γ ′ fi brinogen have an altered clot architecture (18, 25, 26) . The γ ′ chain protects thrombin from inactivation by antithrombin (27) , which appears to contribute to the heparin resistance of clotbound thrombin (28, 29) . This could increase the length of time that thrombin remains active on the clot surface, potentially causing increased thrombus formation. Possibly as a result of these properties, epidemiologic studies suggest that γ ′ fi brinogen may be a risk factor for CVD (11 -16, 30 -33) .
γ ′ Fibrinogen has certain inhibitory properties towards hemostasis, which have lead to the opposite hypothesis that low levels of γ ′ fi brinogen may predispose towards thrombosis (34, 35) . For example, thrombin binding to the γ ′ chain inhibits cleavage of factor VIII (36) , which slows the rate of coagulation. In addition, thrombin binding to the γ ′ chain inhibits thrombin activation of platelets through PAR-1 (37, 38) , which would inhibit hemostasis. The effect of the γ ′ chain on thrombin cleavage of fi brinopeptides A and B has been controversial, with three different results reported from three different laboratories (18, 25, 26) . However, the inhibitory properties of the γ ′ chain towards hemostasis have been proposed as a protective mechanism against venous thrombosis (39) .
γ ′ Fibrinogen and arterial thrombosis
The altered biochemical and biophysical properties of γ ′ fi brinogen compared to total fi brinogen have prompted a series of investigations into its association with CVD. The fi rst epidemiologic study on γ ′ fi brinogen proposed that an elevated ratio of γ ′ fi brinogen to total fi brinogen may be a marker of arterial thrombosis (30) . The underlying hypothesis for this study came from the observation that the γ ′ chain does not bind the platelet receptor α IIb β 3 (GpIIb-IIIa) during platelet aggregation (40 -42) . The hypothesis was that platelet activation during thrombosis would preferentially sequester fi brinogen containing γ A chains, thereby increasing the ratio of γ ′ fi brinogen to γ A fi brinogen in plasma. In this study, γ ′ fi brinogen was measured in control subjects aged 18 -45 years (n = 200) and control subjects aged 65 -85 years (n = 233) for comparison with peripheral arterial disease (PAD) and ischemic stroke patients (n = 179) and PAD, ischemic stroke, and myocardial infarction patients (n = 236). Whether the original hypothesis was correct is still unresolved, but nevertheless the study found an increased γ ′ fi brinogen/total fi brinogen ratio that was correlated with D-dimer levels. Consistent with this hypothesis, ticlopidine treatment, which inhibits platelet activation through the ADP receptor, lowered the γ ′ fi brinogen/ total fi brinogen ratio. One limitation of this study was that multivariate analysis was not performed to calculate the odds ratio for the association of γ ′ fi brinogen with CVD.
The next study to investigate the association of γ ′ fi brinogen with CVD was a small case-control study of coronary artery disease (CAD) (11) . In this study (n = 133), γ ′ fi brinogen levels were measured in patients undergoing elective, outpatient diagnostic cardiac catheterization. Those patients diagnosed with CAD by angiography (n = 91) were considered CAD cases, and the remaining patients (n = 42) were considered controls. The mean γ ′ fi brinogen level in the cases was 0.413 ± 0.016 g/L (mean ± SE) compared to 0.299 ± 0.024 g/L in the controls (p < 0.0001). This study also determined a mean γ ′ fi brinogen level of 0.285 g/L in normal blood donors. The odds ratio comparing the highest to lowest quartile, adjusting only for age and gender, was 7.16 (95 % CI 1.82 -27.7). There was no signifi cant correlation between γ ′ fi brinogen and total fi brinogen levels in this cohort, suggesting that γ ′ fi brinogen was not simply a surrogate marker for total fi brinogen. In contrast to the original paper by Drouet et al. (30) , there was no signifi cant association between the ratio of γ ′ fi brinogen/ total fi brinogen and CAD.
A subsequent epidemiologic study on myocardial infarction was performed in the Stockholm Coronary Artery Risk Factor cohort (12) . This study examined γ ′ fi brinogen levels in younger MI patients, under the age of 60 (n = 387), and in population-based sex-and age-matched controls (n = 387). The mean γ ′ fi brinogen levels were signifi cantly higher in cases (0.28 ± 0.12 g/L; mean ± SD) than controls (0.25 ± 0.11 g/L) (p = 0.001), but there was no signifi cant difference in the γ ′ fi brinogen/total fi brinogen ratio. A weak correlation was found between γ ′ fi brinogen levels and total fi brinogen levels in both patients ( r = 0.29) and controls ( r = 0.18). γ ′ Fibrinogen levels were signifi cantly associated with MI in a multivariate model (OR = 1.24; 95 % CI 1.01 -1.52), after adjustment for age, gender, smoking, alcohol consumption, body mass index (BMI), total fi brinogen, interleukin-6, insulin, triglycerides, and high density lipoprotein (HDL)-cholesterol. Single nucleotide polymorphisms (SNPs) were also investigated for their association with γ ′ fi brinogen levels. One interesting allele in particular, FGG 9340T > C (rs1049636), occurs in intron 9 between the exon 9/intron 9 splice site and the γ ′ mRNA polyadenylation site within intron 9 ( Figure 1 ). FGG 9340C was associated with signifi cantly higher γ ′ fi brinogen levels, while the FGA 2224A (rs2070011) allele was associated with lower γ ′ fi brinogen levels. However, although the FGG 9340T and FGA 2224G alleles were signifi cantly associated with γ ′ fi brinogen levels, neither was associated with MI. In addition, since these were haplotype-tagging SNPs, the possibility remained that they were simply proxies for functional SNPs located elsewhere in the fi brinogen gene locus.
The issue of genetic modifi ers of γ ′ fi brinogen and their association with arterial thrombosis has been further investigated in a pediatric cohort from the German study center Muenster (43) . An independent family-based cohort of 268 nuclear families with thromboembolic nonvascular stroke showed a signifi cant association of the FGG-H2 haplotype with stroke. This haplotype includes two SNPs in the intron 9/exon 10 region (Figure 1 ), FGG 9615C > T (rs2066864) and FGG 10,034C > T (rs2066865). The 10,034T allele is located within a GT-rich downstream sequence element in a potential cleavage stimulation factor binding site, and has been shown to decrease the ratio of γ ′ / γ A mRNA in a minigene construct (44) . The 10,034T allele has also been associated with decreased γ ′ fi brinogen levels and a decreased γ ′ fi brinogen/total fi brinogen ratio (34) . 10,034T is a haplotype-tagging SNP for the FGG-H2 haplotype. Although carriers of the FGG-H2 haplotype did have decreased γ ′ fi brinogen levels and lower γ ′ fi brinogen/total fi brinogen ratios, as shown previously (34) , the study design precluded any calculations of odds ratios for γ ′ fi brinogen levels and stroke (43) .
More problematic, the FGG-H2 haplotype is in linkage disequilibrium with an A α chain polymorphism in the coding region, FGA Thr312Ala (rs6050), near the factor XIIIa α -fi brin/ α -fi brin cross-linking site at A α 328 (45) . The Ala312 variant produces stiffer clots with increased α chain crosslinking, larger fi ber diameters, and a lower number of fi bers per unit area (46) . The rs6050 SNP itself has been associated with stroke risk, and the A2 haplotype containing the minor allele of rs6050 showed a signifi cant association with ischemic stroke (OR 1.4; 95 % CI 1.1 -1.8) (47) . There are therefore at least two functional SNPs in the FGG-H2 haplotype, FGG 10,034C > T (rs2066865) that results in decreased γ ′ fi brinogen levels, and FGA Thr312Ala (rs6050) that results in increased α chain cross-linking, larger fi ber diameters, and a lower number of fi bers per unit area. Therefore, ascribing decreased γ ′ fi brinogen levels as the cause of the association of the FGG-H2 haplotype with increased stroke risk, may be a premature conclusion.
In contrast, another case-control study (n = 249) found that an elevated γ ′ fi brinogen/total fi brinogen ratio was associated with the acute phase of ischemic stroke, but was lower 3 months after stroke during the convalescent phase (14) . The FGG-H2 haplotype, although associated with decreased γ ′ fi brinogen levels, was not associated with risk of stroke. In contrast, the FGG-H3 haplotype was associated with reduced risk of stroke, but was not associated with the γ ′ fi brinogen/ total fi brinogen ratio. The authors concluded that the increase in γ ′ fi brinogen levels during the acute phase may actually be a result of the event, rather than the cause, and suggested that the acute phase may affect the alternative splicing events that give rise to the γ ′ mRNA. A follow-up study (n = 356) by several of these authors demonstrated a signifi cant association between unfavorable stroke outcome (Rankin Scale score > 2) and elevated γ ′ fi brinogen levels, independent of total fi brinogen, as well as an elevated γ ′ fi brinogen/total fi brinogen ratio (33) . The odds ratio for an unfavorable outcome per unit increase in γ ′ fi brinogen was 1.48 (95 % CI 1.15 -1.91) after adjustment for age, sex, and time to blood draw. The authors concluded that the absolute levels of γ ′ fi brinogen may be more important than the γ ′ fi brinogen/total fi brinogen ratio.
The relationship between γ ′ fi brinogen levels and known CVD risk factors was investigated in the Framingham Heart Study (13) . γ ′ Fibrinogen levels were signifi cantly associated with several known CVD risk factors in the Framingham Offspring cohort (n = 3300), including age, sex, BMI, smoking, diabetes, blood glucose, and triglycerides, and inversely associated with HDL levels. The reference interval, defi ned as the 2.5th and 97.5th percentile limits for γ ′ fi brinogen in health individuals without CVD, was 0.088-0.551 g/L. The range of γ ′ fi brinogen measured in these samples varied nearly 40-fold, from 0.037 g/L to 1.443 g/L.
A subsequent community-based study and a genome-wide association study of γ ′ fi brinogen levels were also performed in the Framingham Heart Study (32) . Individuals with prevalent CVD had signifi cantly elevated γ ′ fi brinogen levels (p = 0.002) compared to those without CVD, 0.278 ± 0.006 g/L vs. 0.258 ± 0.002 g/L. Analyzing the relationship between γ ′ fi brinogen and CVD, the odds ratio of an event per 0.1 g/L increase in γ ′ fi brinogen was 1.12 (95 % CI 1.03 -1.21) after adjustment for sex, age, BMI, systolic blood pressure, fasting blood glucose, diabetes mellitus, smoking, total cholesterol, HDL cholesterol, and triglycerides. In a multivariate model comparing the prevalence of CVD between the highest and lowest tertiles, the adjusted odds ratio was 1.53 (95 % CI 1.14 -2.05). The association between γ ′ fi brinogen and myocardial infarction was even higher, with an adjusted odds ratio of 1.76 (95 % CI 1.06 -2.92).
The odds of CVD and myocardial infarction were increased for individuals who were in the highest tertiles of both γ ′ fi brinogen and total fi brinogen. Whereas individuals in the highest tertile of γ ′ fi brinogen had an adjusted odds ratio of 1.76 for myocardial infarction, and individuals in the highest tertile of total fi brinogen had an adjusted odds ratio of 1.99 (95 % CI 1.21 -3.28), those in the highest tertiles of both γ ′ fi brinogen and total fi brinogen had an adjusted odds ratio of 3.08 (95 % CI 1.41 -6.72). These results suggest that γ ′ and total fi brinogen are not simply surrogate markers for one another, but that each analyte adds predictive power to risk assessment for CVD.
In a genome-wide association study examining 2.5 million SNPs, 54 SNPs in or near the fi brinogen gene locus demonstrated genome-wide signifi cance (32) . The top-signal SNP was rs7681423 in the fi brinogen gene locus near FGG , although the top two SNPs associated with γ ′ fi brinogen levels were not associated with CVD. These results suggest that genetics may not play a major role in the association between γ ′ fi brinogen and CVD. These fi ndings contrast those for total fi brinogen levels, which are associated with different genetic loci, particularly FGB encoding the B β chain of fi brinogen. Since γ ′ fi brinogen is an acute phase reactant that increases in response to infl ammation, these results suggest that environmental factors may play a greater role than genetic factors in its association with CVD.
γ ′ Fibrinogen and infl ammation
The association between γ ′ fi brinogen and arterial thrombosis may be due, at least in part, to the association between γ ′ fi brinogen and infl ammation. Infl ammation is now a wellestablished risk factor for arterial thrombosis (48) , and γ ′ fi brinogen has shown a strong association with infl ammation in several published studies. In the case-control stroke study mentioned above (14) , γ ′ fi brinogen levels were increased during the acute phase of stroke when C-reactive protein (CRP) levels were elevated, and decreased during the convalescent phase when CRP levels decreased. Furthermore, the ratio of γ ′ fi brinogen/total fi brinogen was also increased during the acute phase compared to the convalescent phase.
Subsequent studies showed that γ ′ fi brinogen was highly associated with C-reactive protein (CRP) levels, and may represent a new marker for infl ammation (16) . γ ′ Fibrinogen levels were measured in patients from the Periodontitis and Vascular Events study (n = 284) (16) . These patients had a history of recent CVD within the last 3 years, as well as periodontal disease. The mean γ ′ fi brinogen level in this cohort appeared to be highly elevated compared to historical controls, 0.622 ± 0.017 g/L (mean ± SE), although no formal comparison to controls was presented, and the percentage of γ ′ fi brinogen was 18.6 %± 0.62 % of total fi brinogen, compared to historical controls of 7.2 % (11) and 6.8 % (13) .
γ ′ Fibrinogen showed a signifi cant association with CRP levels (p = 0.006 after adjustment for age, gender, smoking status, BMI, type 2 diabetes, and total fi brinogen), and a one unit increase in CRP was associated with a 1.9 % increase in γ ′ fi brinogen (16) . In addition, the γ ′ fi brinogen level was highly associated (p < 0.001) with a high-risk CRP level of > 3 mg/L. Each 0.1 g/L increase in γ ′ fi brinogen increased the odds of being in this high-risk group by 20 % (p < 0.001) after adjustment for BMI and total fi brinogen. In contrast, total fi brinogen levels were relatively normal in this cohort, 3.70 g/L, suggesting that γ ′ fi brinogen may display differential regulation from total fi brinogen in the setting of combined CVD history and periodontal infl ammation. Further support for infl ammatory regulation of γ ′ fi brinogen was provided by a case-control study (n = 211) of patients with intracerebral hemorrhage (49) in which the authors proposed that the absolute rise in γ ′ fi brinogen observed in their study is an acute phase response.
γ ′ Fibrinogen and venous thrombosis
The association between γ ′ fi brinogen and venous thromboembolism (VTE) is much more controversial. The fi rst publication on this subject, a case-control study (n = 948) from the Leiden Thrombophilia Study, showed a signifi cant association between the FGG-H2 haplotype and VTE (34) . This association was replicated in a subsequent study case-control study of VTE (n = 712) using samples from the Medical University Graz (50) . The FGG-H2 haplotype contains the FGG 10,034C > T SNP (rs2066865), which is associated with decreased γ ′ fi brinogen levels. However, as mentioned earlier, this SNP is in linkage disequilibrium with the FGA Thr312Ala (rs6050) polymorphism that results in stiffer clots with increased A α chain cross-linking, larger fi ber diameters, and a lower number of fi bers per unit area (46) . The authors ' hypothesis was that γ ′ fi brinogen was protective against VTE by virtue of its "antithrombin I" activity (39) . This is an activity described over half a century ago as an inhibitory activity of fi brin towards thrombin (51) . The hypothesis proposed that the γ ′ chain high affi nity binding site for thrombin sequestered active thrombin. As a result, less free thrombin was available to cleave its substrates. These fi ndings lead to a model in which low γ ′ fi brinogen levels caused reduced sequestration of thrombin, resulting in a hypercoagulable state and VTE (31) . This mechanism was also proposed to explain the association between low γ ′ fi brinogen levels and thrombotic microangiopathy in a case-control study (n = 87) (35) .
There is biochemical support for this hypothesis as well. Binding of the γ ′ chain to thrombin allosterically modulates the active site (52) . This antithrombin I activity inhibits thrombin activation of coagulation under static conditions by inhibiting factor VIII cleavage (36) . In addition, this activity inhibits thrombin activation of platelets by inhibiting PAR1 cleavage (37, 38) . Studies with transgenic mice containing the human fi brinogen thrombin-binding γ ′ chain sequence showed a decrease in thrombosis (53) .
However, a more recent publication showed results that are opposite to those found in Uitte de Willige et al. (34) . In a cross-sectional study of newly-diagnosed pulmonary embolism (PE) patients (n = 29), γ ′ fi brinogen levels showed the highest levels of γ ′ fi brinogen ever published in a clinical study, 0.79 ± 0.33 g/L (mean ± SD) during the acute phase of PE (15) .
A competing hypothesis of the role of the γ ′ chain may provide an alternative explanation for these results. Binding of thrombin to the γ ′ chain in humans changes thrombin ' s cleavage of its substrates in a manner analogous to the binding of thrombin to thrombomodulin (54) or platelet glycoprotein Ib α (GPIb α ) (55) . For example, activation of factor VIII in the intrinsic pathway by thrombin cleavage is impaired by the γ ′ chain, and the activated partial thromboplastin time is prolonged (36) . In contrast, binding of the γ ′ chain to thrombin does not inhibit the cleavage of small peptide substrates, nor completely inhibit cleavage of fi brinogen (36) , but may modulate the kinetics of fi brinopeptide A and B release (18, 25, 26) . A competing hypothesis is that thrombin bound to the γ ′ chain continues to convert more fi brin at the site of clot formation, although it restricts thrombin cleavage of other substrates. The γ ′ chain also protects thrombin from inactivation by antithrombin (27) . This would potentially allow continued clot formation at the site where fi brin is being deposited, while preventing diffusion of thrombin due to blood fl ow. In this model, γ ′ fi brinogen, rather than being an antithrombin, would serve as a reservoir for active thrombin at the growing clot surface.
Another potential explanation for the discrepancies between the inverse and positive associations with VTE and γ ′ fi brinogen in studies by Uitte de Willige et al. (34) and Cheung et al. (15) , respectively, may be in the experimental design. The study by Uitte de Willige et al. (34) was case-control in nature, using age-and gender-matched controls for VTE cases. However, no adjustment was made for warfarin use in this study. Since γ ′ fi brinogen is an infl ammatory marker, and warfarin is known to decrease systemic infl ammation, it is possible that the VTE cases who were exposed to warfarin had decreased infl ammation and therefore decreased γ ′ fi brinogen levels in the blood samples taken after the event. In contrast, in the study by Cheung et al. (15) , blood samples were taken at the time of the VTE event prior to warfarin exposure and compared to normal population controls (n = 173), although the controls were not matched to the cases. A more defi nitive way to control for warfarin exposure would be to conduct a prospective study with a nested case/cohort design. However, since no such prospective studies have yet been performed the association between γ ′ fi brinogen and VTE remains controversial. Further studies will be necessary to defi nitively address the association between γ ′ fi brinogen and VTE.
Conclusions and perspectives
γ ′ Fibrinogen is a newly-emerging risk factor for CVD that is upregulated during infl ammation. The biochemical properties of γ ′ fi brinogen provide support for the hypothesis that, unlike many CVD risk biomarkers, γ ′ fi brinogen may play a mechanistic role in thrombosis. The increased fi brinolytic resistance and altered clot architecture of γ ′ fi brinogen provide potential mechanisms to explain the association with thrombosis. In addition, the presence of a high-affi nity thrombin binding site on the γ ′ chain, and the consequent resistance of the bound thrombin to antithrombin inhibition, may also play a mechanistic role in facilitating thrombosis. In contrast, the inhibitory properties of γ ′ fi brinogen towards hemostasis, particularly the inhibition of factor VIII cleavage and PAR-1 cleavage by thrombin, present a plausible mechanism for an inverse association with VTE. However, the epidemiologic association of γ ′ fi brinogen and VTE is still unresolved.
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